<DOC>
	<DOCNO>NCT01470937</DOCNO>
	<brief_summary>This evaluation effect acarbose delay worsen fast glucose control early Type 2 diabetes mellitus .</brief_summary>
	<brief_title>Early Diabetes Intervention Program</brief_title>
	<detailed_description>A double blind , randomize , placebo-controlled clinical trial acarbose subject type 2 diabetes ( FDA-approved indication ) . Subjects identify diabetes glucose tolerance test criterion non-diabetic fast glucose concentration . Treatment intervention assess ability delay worsen fast glucose control .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<criteria>Fasting plasma glucose &lt; 140 mg/dL 75 g OGTT 2hr glucose &gt; 120 mg/dL BMI &gt; 25 OR history gestational diabetes mellitus OR family history type 2 diabetes Age least 25 year Cancer within 5 year Chronic infectious disease ( HIV , Hepatitis ) CVD event within 6 month Uncontrolled hypertension require beta blocker thiazide diuretic control elevate AST ALT Serum creatinine &gt; 1.4 mg/dL ( men ) &gt; 1.3 mg/dL ( woman ) TG &gt; 600 mg/dL Known glucosidase intolerance Inability comply protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>diabetes acarbose alphaglucosidase prevention</keyword>
</DOC>